References

References for drug testing

  1. Thompson D, "Giving up on the mice", Time , 17 Sept 1990 (79)
  2. Kano Y et al, "Effects of CPT-11 in combination with other anti-cancer agents in culture", International Journal of Cancer , 1992, vol 50 (604-610)
  3. Aiba K et al, "Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line", Gan To Kagaku Ryoho , 1994, vol 21 (1601-1606)
  4. Liebman J et al, "Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines", British Journal of Cancer , 1993, vol 68 (1104-1109)
  5. Zoli W et al, "In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers", Breast Cancer Research and Treatment , 1995, vol 34 (63-69)
  6. Sevin B & Perras J, "Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer", American Journal of Obstetrics and Gynaecology , 1997, vol 176 (759-766)
  7. Reitz M et al, "Detection of DNA damage in stimulated human lymphocytes after adding cytostatic drugs in vitro. A model to demonstrate individual damage rates", Arzneimittelforschung , 1997, vol 47 (88-91)
  8. Ho W et al, "L-2-oxothiazolidine-4-carboxylic acid inhibits human immunodeficiency virus type 1 replication in mononuclear phagocytes and lymphocytes", Clinical Diagnostic and Laboratory Immunology , 1997, vol 4 (352-357)
  9. Parang K et al, "In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses", Antiviral Research , 1997, vol 34 (75-90)
  10. Maragos C et al, "Antibody response to the herpes simplex virus type 2 Ag-4 antigen in guinea pigs with genital herpes infection", Australian Journal of Experimental Biology and Medical Science , 1986, vol 64 (89-95)
  11. Hayashi K et al, "Characterisation of antiviral activity of a sesquiterpene triptofordin C-2", Journal of Antimicrobials and Chemotherapy , 1996, vol 37 (759-768)
  12. Weiss L et al, "Anti-hepatitis B virus activity of N-acetyl-L-cysteine (NAC): new aspects of a well-established drug", Antiviral Research , 1996, vol 32 (43-53)
  13. Zhang Y & Coulter D, "Anticonvulsant drug effects on spontaneous thalamocortical rhythms in vitro: phenytoin, carbamazepine, and phenobarbital", Epilepsy Research , 1996, vol 23 (55-70)
  14. Zhang Y et al, "Anticonvulsant drug effects on spontaneous thalamocortical rhythms in vitro: valproic acid, clonazepam, and alpha-methyl-alpha-phenylsuccinimide", Epilepsy Research , 1996, vol 23 (37-53)
  15. Tabatabaei A et al, "A rapid in vitro assay for evaluation of metabolism-dependent cytotoxicity of antiepileptic drugs on isolated human lymphocytes", Fundamental and Applied Toxicology , 1997, vol 37 (181-189)
  16. Ounissi-Benkalha H et al, "In vitro effect of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis", Journal of Rheumatology , 1996, vol 23 (16-23)
  17. Utoguchi N et al, "Bruceine B, a potent inhibitor of leukocyte-endothelial cell adhesion", Inflammation , 1997, vol 21 (223-233)
  18. Rocca-Ferrer J et al, "Effect of topical anti-inflammatory drugs on epithelial cell-induced eosinophil survival and GM-CSF secretion", European Respiratory Journal , 1997, vol 10 (1489-95)
  19. Pfeiffer S et al, "Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol", European Journal of Medical Research , 1997, vol 2 (129-132)
  20. Katzung B, Basic and Clinical Pharmacology (6th ed), East Norwalk CT: Appleton and Lange, 1995
  21. Richards W, "Computer simulation in drug research", ATLA , 1995, vol 23 (784-788)
  22. Sharpe R, The Cruel Deception: The Use of Animals in Medical Research , Wellingborough: Thorsons Publishing Group, 1988
  23. Carson S et al, "A continuing toxicologic reassessment of isoprenaline aerosols", The Pharmacologist , 1971, vol 18 (272)
  24. Collins M et al, "The cardio-toxicity of isoprenaline during hypoxia", British Journal of Pharmacology , 1969, vol 36 (35-45)
  25. Anon, "S.M.O.N. and clioquinol", The Lancet , 1977 March 5, (534)
  26. Tsubaki T et al, "Neurological syndrome associated with clioquinol", The Lancet , 1971 April 3 (696-697)
  27. Hess R et al, "Clioquinol: absence of neurotoxicity in laboratory animals", The Lancet , 1972 August 26 (424-425)
  28. Anon, "Benoxaprofen", British Medical Journal , 1982, vol 285 (459-460)
  29. Buttinoni A et al, "Pharmacological study on a new analgesic anti-inflammatory drug", Arzneimittel Forschung , 1973, vol 23 (1100-1107)
  30. Heel R et al, "Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness", Drugs , 1982, vol 24 (169-206)
  31. Venning G, "Identification of adverse reactions to new drugs. I: What have been the most important adverse reactions since thalidomide?" British Medical Journal , 1983, vol 286 (199-202)
  32. Weatherall M, "An end to the search for new drugs?" Nature , 1982, vol 296 (387-390)
  33. Gray J et al, "The oral toxicity of clindamycin in laboratory animals", Toxicology and Applied Pharmacology , 1972, vol 21 (516-531)
  34. Anon, "Oral ketoconazole and liver damage", The Lancet , 1985 January 12 (121)
  35. Anon, "Toxic hepatitis during ketoconazole treatment", British Medical Journal , 1981, vol 283 (825)
  36. Carlson P, "The failure of animal experiments, part II", Good Medicine , Summer 1996 (7-8)
  37. Cohen A, "Dangers of non-sedating antihistamines", The Lancet , 1997, vol 350 (69)
  38. Curfman G, "Diet pills Redux", New England Journal of Medicine , 1997, vol 337 (629-630)
  39. British Medical Journal 1997 vol 314 3 May 1299
  40. Litchfield, cited in Koppanyi T & Avery M, "Species differences and the clinical trial of new drugs: a review", Clinical Pharmacology and Therapeutics , 1966, vol 7 (250-267)
  41. Fletcher A, "Drug safety tests and subsequent clinical experience", Journal of the Royal Society of Medicine , 1978, vol 71 (693-696)
  42. Anon, "Phenylbutazone and oxyphenbutazone: FDA considers petition for ban in United States", The Lancet , 1984 January 11 (353)
  43. Birkett D et al, "In vitro approaches can predict human drug metabolism", Trends in Pharmacological Science , 1993, vol 14 (292-294)
  44. Beaune P & Guengerich F, "Human drug metabolism in vitro", Pharmacology and Therapeutics , 1988, vol 37 (193-211)
  45. Guillouzo A et al, "use of human hepatocyte cultures for drug metabolism studies", Toxicology , 1993, vol 82 (209-219)
  46. Wrighton S et al, "In vitro methods for assessing human hepatic drug metabolism: their use in drug development", Drug Metabolism Reviews , 1993, vol 25 (453-484)
  47. Peck C et al, "Understanding consequences of concurrent therapies", Journal of the American Medical Association , 1993, vol 269 (1550-1552)
  48. Rodrigues A, "Use of in vitro human metabolism studies in drug development: an industrial perspective", Biochemical Pharmacology , 1994, vol 48 (2147-2156)
  49. Houston J, "Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance", Biochemical Pharmacology , 1994, vol 47 (1469-1479)
  50. Riley R & Leeder J, "In vitro analysis of metabolic predisposition to drug hyper-sensitivity reactions", Clinical and Experimental Immunology , 1995, vol 99 (1-6)
  51. Hidalgo I et al, "Characterisation of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability", Gastroenterology , 1989, vol 96 (736-749)
  52. Veronesi B et al, "An in vitro model of the blood-brain barrier: the response of Madin-Darby canine kidney cells to triethyl tin", ATLA , 1996, vol 24 (349-357)